Pathogenetic justification of the use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.

Introduction. Benign prostatic hyperplasia (BPH) is one of the commonest urological diseases. Aim. To review current research on use 5-alfa-reductase inhibinors (5-ARI) in treatment BPH: finasteride and dutasteride. Materials methods. We have done a search analysis publications for last 20 years using elibrary, PubMed, Cochrane Collaboration Embase databases. The inclusion criteria were: prospective (cohort) studies randomized clinical trials (RCTs). total number sources included this was 36. Results discussion. highlights following sections: side effects 5-ARI inhibitors, evaluation effectiveness therapy with inhibitors reasons its inefficiency, conclusions. works devoted to showed absence complete cure BPH against background modern pharmacotherapy moderate positive effect most patients. known suggest there are additional mechanisms those medications besides inhibiting enzyme 5-alpha-reductase new needed identify them. lack generally accepted indicators monitoring makes it difficult assess it. And insufficient drug may be associated inability classify pathophysiological diversity disease phenotypes. Conclusions. New study individual specific composition pancreatic tissue deeper understanding pathogenesis disease, which will improve results develop therapeutic solutions